Rapid Micro Biosystems Expands Series C Round With Investment From EDBI
(Thomson Reuters ONE) -
LOWELL, Mass., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, a
leading provider of automated, non-destructive, rapid microbial detection, today
announced the expansion of its recent Series C equity financing with an
investment from EDBI, the dedicated corporate investment arm of the Singapore
Economic Development Board. This investment will be used to expand global
commercial and manufacturing operations in support of the Rapid Micro Biosystems
Growth DirectTM, an industry-leading system for faster detection of microbial
contamination in the manufacture of pharmaceutical, biotechnology, medical
device and personal care products.
The Growth Direct(TM) System detects microbial contamination earlier across all
key applications of environmental monitoring, bioburden and sterility testing,
delivering compelling economic benefits to healthcare product manufacturers
while improving their microbial quality processes. In use by some of the largest
organizations in the world, the Growth Direct(TM) System is the first and only
automated technology that addresses all microbial quality control applications
and fits with current regulatory practices.
"With our growing customer base in Asia, and specifically in Singapore, the
partnership with EDBI will accelerate Rapid Micro Biosystems' strategic focus of
growing our commercial and operational capabilities in the region," said Robert
Spignesi, CEO of Rapid Micro Biosystems.
"Rapid Micro Biosystems will enable Singapore's pharmaceutical and medical
technology plants to capture substantial and sustainable productivity gains. We
are excited to assist the company in gaining access to the fast-growing Asian
market from Singapore through our network in the region," said Chu Swee Yeok,
CEO and President of EDBI.
About Rapid Micro Biosystems
Rapid Micro Biosystems delivers the Growth Direct(TM) System, an automated, non-
destructive rapid detection and enumeration technology based on the compendial
method for microbial quality control in pharmaceutical manufacturing. The
system automates and accelerates detection and enumeration in the areas of
sterility testing, environmental monitoring, and bioburden testing, eliminating
manual steps and analysis. The detection technology, first developed and
patented by Dr. Don Straus, Ph.D., uses the natural auto-fluorescence of
microbes and requires no reagents. For more information about Rapid Micro
Biosystems visit www.rapidmicrobio.com
Contact:
Mark Severns
Rapid Micro Biosystems
978-349-3200
mseverns(at)rapidmicrobio.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Rapid Micro Biosystems via GlobeNewswire
[HUG#1944921]
Datum: 11.08.2015 - 15:00 Uhr
Sprache: Deutsch
News-ID 412909
Anzahl Zeichen: 3381
contact information:
Town:
Lowell, MA
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 165 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Rapid Micro Biosystems Expands Series C Round With Investment From EDBI"
steht unter der journalistisch-redaktionellen Verantwortung von
Rapid Micro Biosystems (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
